UTEC has returned to co-lead a $14m funding round for ImmunoScape, which will use the money to bolster its presence in Singapore and the US.
ImmunoScape, a Singapore-based immunonics platform developer spun out of the Agency for Science, Technology and Research (A*Star), pocketed $14m in a funding round co-led by University of Tokyo Edge Capital Partners (UTEC) yesterday.
Anzu Partners and EDBI, the investment arm of the Economic Development Board of Singapore, co-led the round.
ImmunoScape is working on a deep immunomics platform that can provide reproducible immune profiling information. The technology can be used to better understand the safety and efficacy of immunotherapies and to identify drug targets.
The latest cash injection will enable ImmunoScape to grow its headcount in Singapore to support in-house R&D activities and external partnerships. The money will also help it double down on expansion plans in the US, including building out a laboratory in San Diego.
Nori Kurokawa, a partner at UTEC, said: “Since the series A financing led by UTEC, ImmunoScape has made remarkable…
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
